UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. stock has experienced a 75.74% increase from February 3, 2025, to February 2, 2026. The stock experienced a significant single-day drop of 44.7% following an FDA AdCom rebuke regarding UGN-102 for bladder cancer. The stock dropped 9.0% after UroGen Pharma reported Q1 2025 financial results. The stock saw a 9.3% decrease following the announcement of Chris Degnan as Chief Financial Officer. UroGen Pharma unveiled positive long-term results from a five-year extension of its Phase 2b OPTIMA II study for ZUSDURI. Analyst sentiment remained robust, with 7 buy ratings against 1 hold and no sell ratings. Short interest decreased by 20.45% from the prior report.

Specific detailed information on the demand seasonality for UroGen Pharma Ltd.'s products and services is not readily available. Demand might not follow a predictable seasonal pattern but rather be influenced by clinical trial progress, regulatory approvals, and product launches. The commercialization of ZUSDURI is complex due to its procedure-based nature, requiring operational support, reimbursement education, and nurse training. The establishment of a permanent J-code for ZUSDURI is expected to streamline reimbursement and boost physician confidence, which could influence adoption rates.

UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, operating within the healthcare sector. Their core technology, RTGel, is designed for sustained drug release to improve therapeutic profiles. Key products include Jelmyto, approved for low-grade upper tract urothelial carcinoma, and ZUSDURI, approved for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company also has a pipeline of investigational product candidates including UGN-102, UGN-103, UGN-104, UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine.

UroGen Pharma Ltd. is based in Princeton, New Jersey, United States, and is also headquartered in Ra'Anana, Israel. The company focuses on delivering therapies to key urology and oncology centers across the United States through its commercial team and strategic partnerships.

UroGen Pharma's brand reputation has been influenced by positive clinical data and regulatory challenges. Positive analyst ratings and strong financial outlooks, including Q3 net product revenue of $25.7 million from JELMYTO and accelerating uptake for ZUSDURI, contribute positively. The FDA AdCom's rebuke for UGN-102 led to stock drops and investigations, negatively impacting reputation. The establishment of a permanent J Code for ZUSDURI is expected to enhance reimbursement clarity and support sustained revenue growth, positively impacting the company's reputation.

UroGen Pharma Ltd. has 246 institutional owners and shareholders holding a total of 46,720,122 shares. Major institutional owners include RTW Investments, LP, Paradigm Biocapital Advisors LP, Toronto Dominion Bank, BlackRock, Inc., Morgan Stanley, Jefferies Financial Group Inc., Silverarc Capital Management, LLC, Millennium Management Llc, SG Americas Securities, LLC, and Acorn Capital Advisors, Llc.